NCT02161965 (VICTORIA) is a Phase 4 clinical trial of Rivaroxaban in Permanent Atrial Fibrillation, sponsored by University Hospital, Angers.

Who is sponsoring NCT02161965?

NCT02161965 is sponsored by University Hospital, Angers.

What drugs are being tested in NCT02161965?

Interventions in NCT02161965: Rivaroxaban, Fluindione, Warfarin.

What condition does NCT02161965 study?

NCT02161965 studies Permanent Atrial Fibrillation, Venous Thrombosis, Pulmonary Embolism, Anticoagulation Treatment at Least > or = to 12-month.

Is NCT02161965 still recruiting?

NCT02161965 is currently completed. Last updated 7 November 2019.

Last reviewed 2019-11-07 · How we verify

NCT02161965: VICTORIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation

Completed Phase 4 Last updated 7 November 2019

What this trial tests

Phase 4 trial testing Rivaroxaban in Permanent Atrial Fibrillation in 51 participants. Completed in 16 February 2018.

Timeline

21 May 2013

Primary endpoint
31 December 2016

16 February 2018

Quick facts

Lead sponsor	University Hospital, Angers
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	51
Start date	21 May 2013
Primary completion	31 December 2016
Estimated completion	16 February 2018
Sites	1 location across France

Drugs / interventions tested

Rivaroxaban (rivaroxaban) — full drug profile →
Fluindione (FLUINDIONE) — full drug profile →
Warfarin (warfarin) — full drug profile →

Conditions studied

Permanent Atrial Fibrillation — all drugs for Permanent Atrial Fibrillation →
Venous Thrombosis — all drugs for Venous Thrombosis →
Pulmonary Embolism — all drugs for Pulmonary Embolism →
Anticoagulation Treatment at Least > or = to 12-month — all drugs for Anticoagulation Treatment at Least > or = to 12-month →

Sponsor

University Hospital, Angers

Who can join

18 and older, any sex, with Permanent Atrial Fibrillation or Venous Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The VICTORIA Study (Vascular CalcIfiCation and sTiffness induced by ORal antIcoAgulation) is a comparative, parallel, prospective, controlled and randomized study of the structural and functional impact of rivaroxaban versus anti-vitamin K drugs on the arterial vasculature.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials.
Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS. · · 2016 · cited 63× · PMID 26985380 · DOI 10.1093/ckj/sfv146

Verify or expand the search:

Other trials of Rivaroxaban

Trials testing the same drug.

NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
NCT07468448 — Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe · Phase 3 · not yet recruiting
NCT07318610 — Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease · Phase 3 · not yet recruiting
NCT07312851 — A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Parti · Phase 1 · recruiting
NCT06961630 — Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction · EARLY_PHASE1 · recruiting

Other University Hospital, Angers trials

Trials by the same sponsor.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07470294 — Effectiveness of Different Surgical Techniques for Curative Treatment of Pilonidal Sinus Disease in the Pediatric Popula · not yet recruiting
NCT07409597 — Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease · NA · not yet recruiting
NCT07468565 — Surgical Approach for the Treatment of Hirschsprung Disease Using the Swenson Technique (SMILES) · not yet recruiting
NCT07452952 — Relationship Between the Level of Positive End-expiratory Pressure and Venous Congestion During Acute Respiratory Distre · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02161965 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Angers
Last refreshed: 7 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02161965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing